Nuveen Asset Management LLC Has $55.32 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Nuveen Asset Management LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 618,406 shares of the medical equipment provider’s stock after selling 72,754 shares during the quarter. Nuveen Asset Management LLC owned about 0.89% of Lantheus worth $55,323,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of LNTH. Janus Henderson Group PLC grew its position in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its position in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after buying an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after buying an additional 435,445 shares during the period. Raymond James Financial Inc. acquired a new position in Lantheus during the fourth quarter valued at approximately $36,183,000. Finally, Swedbank AB grew its holdings in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after purchasing an additional 385,000 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 over the last quarter. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Finally, Truist Financial decreased their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus presently has an average rating of “Buy” and a consensus price target of $132.67.

Lantheus Stock Up 1.8%

Lantheus stock opened at $81.24 on Monday. The stock has a market capitalization of $5.62 billion, a PE ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a twelve month low of $75.00 and a twelve month high of $126.89. The company has a 50 day moving average of $97.11 and a 200-day moving average of $93.08.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.